Development of anti-EGFR targeted magnetic nanoparticles for doxorubicin delivery into triple negative breast cancer cells.
- Ref: Eur J Pharm Biopharm. 2026 May;222:115009.
- Année de publication : 2026
- Auteurs : Lameli C, David S, Allard-Vannier E, Dupeyrol G, Boursin F, Aubrey N, Chourpa I, Hervé-Aubert K